$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420414018114 Filed on March 27, 2014

Income Statement

Concept	2014 Q1	2012 Q4	2012
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$350.0K	$350.0K	$1.750M
YoY Change	-37.5%	-53.33%	-20.81%
% of Gross Profit
Research & Development	$680.0K	$280.0K	$1.770M
YoY Change	30.27%	-57.58%	4.73%
% of Gross Profit
Depreciation & Amortization	$30.00K	$40.00K	$157.0K
YoY Change	0.0%	33.33%	4.67%
% of Gross Profit
Operating Expenses	$1.031M	$630.0K	$3.518M
YoY Change	-4.63%	-55.0%	-9.56%
Operating Profit	-$2.111M		-$3.425M
YoY Change	95.1%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$1.080M	$60.00K	$90.00K
YoY Change		-400.0%	-550.0%
Pretax Income	-$2.110M	-$580.0K	-$1.197M
YoY Change	95.37%	-59.15%	-69.39%
Income Tax	$0.00	$0.00	$5.000K
% Of Pretax Income
Net Earnings	-$2.111M	-$580.0K	-$3.430M
YoY Change	95.1%	-59.15%	-12.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$179.6K	-$57.94K	-$374.0K
COMMON SHARES
Basic Shares Outstanding	176.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2012 Q4	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.030M	$4.090M	$4.090M
YoY Change	-16.76%	113.02%	113.02%
Cash & Equivalents	$3.027M	$1.317M	$1.320M
Short-Term Investments		$2.770M	$2.770M
Other Short-Term Assets	$30.00K	$50.00K	$50.00K
YoY Change	-25.0%	-28.57%	-28.57%
Inventory
Prepaid Expenses	$34.00K	$46.00K
Receivables	$790.0K	$740.0K	$740.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.853M	$4.874M	$4.870M
YoY Change	-10.4%	111.91%	111.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$327.0K	$247.0K	$250.0K
YoY Change	42.17%	-20.32%	-19.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$20.00K	$20.00K
YoY Change	-95.45%	-81.82%	-81.82%
Total Long-Term Assets	$340.0K	$264.0K	$270.0K
YoY Change	-24.44%	-40.0%	-38.64%
TOTAL ASSETS
Total Short-Term Assets	$3.853M	$4.874M	$4.870M
Total Long-Term Assets	$340.0K	$264.0K	$270.0K
Total Assets	$4.193M	$5.138M	$5.140M
YoY Change	-11.73%	87.52%	87.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$326.0K	$358.0K	$360.0K
YoY Change	30.4%	49.17%	50.0%
Accrued Expenses	$1.034M	$605.0K	$610.0K
YoY Change	56.67%	-19.33%	-18.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.607M	$1.156M	$1.160M
YoY Change	51.6%	1.4%	1.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.730M	$0.00	$0.00
YoY Change	723.81%	-100.0%	-100.0%
Total Long-Term Liabilities	$1.726M	$0.00	$0.00
YoY Change	721.9%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.607M	$1.156M	$1.160M
Total Long-Term Liabilities	$1.726M	$0.00	$0.00
Total Liabilities	$3.333M	$1.156M	$1.160M
YoY Change	162.44%	-8.25%	-7.94%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$55.38M	$51.49M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$860.0K	$3.982M	$3.980M
YoY Change
Total Liabilities & Shareholders Equity	$4.193M	$5.138M	$5.140M
YoY Change	-11.73%	87.52%	87.59%

Cashflow Statement

Concept	2014 Q1	2012 Q4	2012
OPERATING ACTIVITIES
Net Income	-$2.111M	-$580.0K	-$3.430M
YoY Change	95.1%	-59.15%	-12.46%
Depreciation, Depletion And Amortization	$30.00K	$40.00K	$157.0K
YoY Change	0.0%	33.33%	4.67%
Cash From Operating Activities	-$391.0K	-$700.0K	-$2.935M
YoY Change	-41.64%	48.94%	32.21%
INVESTING ACTIVITIES
Capital Expenditures	$94.00K	-$10.00K	$90.00K
YoY Change	370.0%	0.0%	-280.0%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	-$2.750M	-$2.750M
YoY Change	-98.99%	27400.0%	13650.0%
Cash From Investing Activities	-$85.00K	-$2.760M	-$2.840M
YoY Change	-108.75%	27500.0%	4633.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$5.023M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$5.169M
YoY Change	-100.0%	-100.0%	25.46%
NET CHANGE
Cash From Operating Activities	-$391.0K	-700.0K	-$2.935M
Cash From Investing Activities	-$85.00K	-2.760M	-$2.840M
Cash From Financing Activities	$0.00	0.000	$5.169M
Net Change In Cash	-$476.0K	-3.460M	-$606.0K
YoY Change	-186.39%	652.17%	-132.93%
FREE CASH FLOW
Cash From Operating Activities	-$391.0K	-$700.0K	-$2.935M
Capital Expenditures	$94.00K	-$10.00K	$90.00K
Free Cash Flow	-$485.0K	-$690.0K	-$3.025M
YoY Change	-29.71%	50.0%	39.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1748000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2917000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29106000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5138000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4726000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	51483000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55138000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1317000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20852000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	2769000	USD
CY2012Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	742000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	4446000	USD
CY2013Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	910000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	4874000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52407000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.03
CY2009	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	775000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	2310000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2101000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	46000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33000	USD
CY2012Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	17000	USD
CY2013Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	22000	USD
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	17000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	22000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	247000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	258000	USD
CY2012Q4	us-gaap	Assets Assets	5138000	USD
CY2013Q4	us-gaap	Assets Assets	4726000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	228000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	605000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	877000	USD
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	193000	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	227000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1156000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1332000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	1156000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1987000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	47508000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	52407000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2007	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1446000	USD
CY2013	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-144000	USD
CY2012	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-93000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52136000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-1743000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150085035	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	176263587	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150085035	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176263587	shares
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1770000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1488000	USD
CY2000Q3	us-gaap	Stockholders Equity StockholdersEquity	0	USD
CY2008	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	33000	USD
CY2010	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	96000	USD
CY2011	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	449000	USD
CY2012	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	195000	USD
CY2013	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	USD
CY2005	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	17506000	USD
CY2006	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	662000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	453000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	3518000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	5018000	USD
	us-gaap	Operating Expenses OperatingExpenses	49958000	USD
CY2012	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	132000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-3425000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-4874000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3430000	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4899000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-52243000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-164000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3430000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.02
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	137596391	shares
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-459000	USD
CY2007	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1232000	USD
CY2008	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	731000	USD
CY2009	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	409000	USD
CY2010	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	388000	USD
CY2011	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1135000	USD
CY2012	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	560000	USD
CY2013	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	674000	USD
CY2005	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	0	USD
CY2006	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	0	USD
	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1168000	USD
CY2010	bcli	Stock Issued During Period Value Conversion Of Convertible Note StockIssuedDuringPeriodValueConversionOfConvertibleNote	135000	USD
CY2011	bcli	Stock Issued During Period Value Conversion Of Convertible Note StockIssuedDuringPeriodValueConversionOfConvertibleNote	140000	USD
CY2008	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	243000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	161071968	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	0	shares
CY2007	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	214000	USD
CY2008	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2009	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2010	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	11000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2419000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-3918000	USD
CY2002	us-gaap	Net Income Loss NetIncomeLoss	-26000	USD
CY2011	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	272000	USD
CY2012	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	9000	USD
	bcli	Adjustments To Additional Paid In Capital Reclassification Due To Application AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication	7191000	USD
CY2007	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	407000	USD
CY2006	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	164000	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	1086000	USD
	bcli	Elimination Of Deferred Stock Compensation Due To Implementation EliminationOfDeferredStockCompensationDueToImplementation	0	USD
CY2007	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Convertible Note Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder	109000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Convertible Note Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder	11000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Loan Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder	110000	USD
CY2007	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	224000	USD
CY2008	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	1276000	USD
CY2009	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	200000	USD
CY2010	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	189000	USD
CY2013	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	30000	USD
CY2007	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	2000000	USD
CY2008	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	1500000	USD
CY2011	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	3602000	USD
CY2012	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	5023000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
CY2010	bcli	Stock Issued During Period Value Previously Subscribed Shares StockIssuedDuringPeriodValuePreviouslySubscribedShares	0	USD
CY2011	bcli	Stock Issued During Period Value Previously Subscribed Shares StockIssuedDuringPeriodValuePreviouslySubscribedShares	24000	USD
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	17000	USD
	bcli	Stock Issued During Period Value Issued For Cash1 StockIssuedDuringPeriodValueIssuedForCash1	60000	USD
CY2004	bcli	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	0	USD
CY2004	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	6000	USD
CY2004	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	0	USD
CY2005	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	0	USD
CY2005	bcli	Stock Issued During Period For Private Placement In June StockIssuedDuringPeriodForPrivatePlacementInJune	60000	USD
CY2002	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	11000	USD
CY2003	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	15000	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	15000	USD
CY2005	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	7000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	8000	USD
CY2009	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1000	USD
CY2010	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1751000	USD
CY2005	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1418000	USD
CY2005	bcli	Amortization Of Deferred Stock Based Compensation Related To Shares And Options Granted To Employees AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees	584000	USD
CY2006	bcli	Amortization Of Deferred Stock Based Compensation Related To Shares And Options Granted To Employees AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees	1174000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In May StockIssuedDuringPeriodForPrivatePlacementInMay	149000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In July StockIssuedDuringPeriodForPrivatePlacementInJuly	99000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In September StockIssuedDuringPeriodForPrivatePlacementInSeptember	225000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In December StockIssuedDuringPeriodForPrivatePlacementInDecember	135000	USD
CY2006	bcli	Forfeiture Of Options Granted To Employees ForfeitureOfOptionsGrantedToEmployees	0	USD
CY2006	bcli	Adjustments To Additional Paid In Capital Reclassification Due To Application AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication	-7906000	USD
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	400000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2497000	USD
CY2010	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	201000	USD
CY2008	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	281000	USD
CY2009	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	729000	USD
CY2010	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	455000	USD
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-6244000	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-3472000	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-1781000	USD
	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	6000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2935000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4054000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18317000	USD
CY2012	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2003	us-gaap	Net Income Loss NetIncomeLoss	-47000	USD
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-73000	USD
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-18840000	USD
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-3317000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3924000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17000	USD
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	-2428000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	-2076000	USD
CY2002Q1	us-gaap	Stockholders Equity StockholdersEquity	53000	USD
CY2003Q1	us-gaap	Stockholders Equity StockholdersEquity	21000	USD
CY2004Q1	us-gaap	Stockholders Equity StockholdersEquity	-31000	USD
CY2005Q1	us-gaap	Stockholders Equity StockholdersEquity	704000	USD
CY2006Q1	us-gaap	Stockholders Equity StockholdersEquity	-7911000	USD
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	-1816000	USD
CY2001Q1	us-gaap	Stockholders Equity StockholdersEquity	68000	USD
	bcli	Stock Issued During Period For Cash In September Price Per Share StockIssuedDuringPeriodForCashInSeptemberPricePerShare	0.00188
	bcli	Stock Issued During Period For Cash In March Price Per Share StockIssuedDuringPeriodForCashInMarchPricePerShare	0.0375
CY2004	bcli	Price Per Share Of Stock Issued During Period To Purchase Mineral Option PricePerShareOfStockIssuedDuringPeriodToPurchaseMineralOption	0.065
CY2005	bcli	Price Per Share Of Stock Issued During Period For Private Placement In June PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJune	0.01
CY2005	bcli	Stock Issued Expenses StockIssuedExpenses	25000	USD
CY2007	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.1818
CY2008	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.1818
CY2005	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.75
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In May PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInMay	0.80
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In July PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJuly	0.60
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In September PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInSeptember	0.80
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In December PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInDecember	0.80
CY2008	bcli	Price Per Share Of Subscription Of Shares During Period For Private Placement PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement	0.1818
CY2010	bcli	Price Per Share Of Subscription Of Shares During Period For Private Placement PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement	0.12
CY2012	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	157000	USD
CY2013	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	97000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1255000	USD
CY2012	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	451000	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1864000	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	195000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	227000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	21908000	USD
CY2012	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	560000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	674000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	8055000	USD
CY2012	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	426000	USD
CY2013	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	155000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	943000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	114000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-130000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	701000	USD
CY2012	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-105000	USD
CY2013	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	306000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1610000	USD
CY2012	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
CY2013	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
CY2013	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-23000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2935000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4054000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18340000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	90000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1331000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-6000	USD
CY2012	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	2750000	USD
CY2013	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-2769000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
CY2012	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
CY2013	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	5000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	22000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2840000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2656000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1347000	USD
CY2012	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2013	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-16000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2840000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2656000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1363000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5023000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3576000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20918000	USD
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	2061000	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	146000	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	785000	USD
CY2012	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
CY2013	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	601000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5169000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3584000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23163000	USD
CY2012	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
CY2013	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	43000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5169000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3584000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23206000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-606000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2186000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3503000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1923000	USD
CY2000Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 58.5pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"></td> <td style="WIDTH: 27pt; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><strong>B.</strong></div> </td> <td style="TEXT-ALIGN: justify; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><strong>Use of <font style="FONT-FAMILY: ; FONT-SIZE: 10pt"> estimates:</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: ; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: ; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	795000	USD
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	918000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1113000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5073000	USD
CY2004Q2	bcli	Common Stock Transferred As Per Purchase Agreement CommonStockTransferredAsPerPurchaseAgreement	6880000	shares
CY2012Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	108000	USD
CY2013Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	60000	USD
CY2012Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	634000	USD
CY2013Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	850000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1256000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1365000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1009000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1107000	USD
CY2012	us-gaap	Depreciation Depreciation	157000	USD
CY2013	us-gaap	Depreciation Depreciation	97000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	126000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	121000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	90000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	337000	USD
CY2013	bcli	Grants Underlying Basis GrantsUnderlyingBasis	The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2013	bcli	Amounts Of Grants Received AmountsOfGrantsReceived	942000	USD
CY2011Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	11001378	shares
CY2012Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	11795801	shares
CY2012	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	794423	shares
CY2013	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	809696	shares
CY2013Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber	12605497	shares
CY2011Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	0.27
CY2012Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	0.27
CY2012	bcli	Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued	0.26
CY2013	bcli	Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued	0.24
CY2013Q4	bcli	Share Based Goods And Nonemployee Services Transaction Securities Outstanding Weighted Average Issue Price ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice	0.27
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1120000	shares
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	20000	USD
CY2012	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	195000	USD
CY2013	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	197000	USD
CY2012	bcli	Research And Development Cost ResearchAndDevelopmentCost	2688000	USD
CY2013	bcli	Research And Development Cost ResearchAndDevelopmentCost	4030000	USD
	bcli	Research And Development Cost ResearchAndDevelopmentCost	33551000	USD
CY2012	bcli	Research And Development Expense Reverse Accruals ResearchAndDevelopmentExpenseReverseAccruals	0	USD
CY2013	bcli	Research And Development Expense Reverse Accruals ResearchAndDevelopmentExpenseReverseAccruals	0	USD
	bcli	Research And Development Expense Reverse Accruals ResearchAndDevelopmentExpenseReverseAccruals	760000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.0833	pure
CY2012	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	239000	USD
CY2013	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	248000	USD
CY2012	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
CY2013Q4	bcli	Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Available For Future Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForFutureGrant	8310937	shares
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	3685000	USD
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22067000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25156000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8340000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8961000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8340000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8961000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1197000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1379000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2233000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3694000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3430000	USD
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Trading Symbol TradingSymbol	BCLI
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	176263587	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	25010064	USD
CY2013	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	between 1-for-10 and 1-for-20
CY2012Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5700000	USD
CY2013Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4000000	USD
CY2013	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
CY2013	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
CY2013	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	781000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	872000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29544000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	655000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	655000	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-174000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-174000	USD
CY2013	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	829000	USD

Files In Submission

Name	View Source	Status
0001144204-14-018114-index-headers.html	Edgar Link	pending
0001144204-14-018114-index.html	Edgar Link	pending
0001144204-14-018114.txt	Edgar Link	pending
0001144204-14-018114-xbrl.zip	Edgar Link	pending
bcli-20131231.xml	Edgar Link	completed
bcli-20131231.xsd	Edgar Link	pending
bcli-20131231_cal.xml	Edgar Link	unprocessable
bcli-20131231_def.xml	Edgar Link	unprocessable
bcli-20131231_lab.xml	Edgar Link	unprocessable
bcli-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ft0001img-1.jpg	Edgar Link	pending
ft0001img-2.jpg	Edgar Link	pending
ft0001img-3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v368979_10k.htm	Edgar Link	pending
v368979_ex21.htm	Edgar Link	pending
v368979_ex23-1.htm	Edgar Link	pending
v368979_ex23-2.htm	Edgar Link	pending
v368979_ex31-1.htm	Edgar Link	pending
v368979_ex31-2.htm	Edgar Link	pending
v368979_ex32-1.htm	Edgar Link	pending
v368979_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2014 Q1 Form 10-K Financial Statement

#000114420414018114 Filed on March 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2014 Q1 Form 10-K Financial Statement

#000114420414018114 Filed on March 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli